서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 17 of 17

Issue DateTitle / Author(s) / CitationFileAltmetrics
2010-08
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
DOI
2011-06
Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization
DOI
2011-11
Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

Kim, Min A.; Lee, Hyuk-Joon; Yang, Han-Kwang; Bang, Yung-Jue; Kim, Woo Ho

Histopathology, Vol.59 No.5, pp.822-831

DOI
2011-12
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib
DOI
2013-07
HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer
DOI
2014-07
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
DOI
2014-12
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
DOI
2015-01
Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
DOI
2015-06
Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer
DOI
2015-07
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
DOI
2016-02
Pertuzumab in gastrointestinal cancer

Oh, Do-Youn; Bang, Yung-Jue

Expert Opinion on Biological Therapy, Vol.16 No.2, pp.243-253

DOI
2016-09
Therapeutic implication of HER2 in advanced biliary tract cancer
DOI
2016-10
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
DOI
2019-07
Acquired resistance of MET-amplified non-small cell lung cancer cells to the MET inhibitor capmatinib

Kim, Seulki; Kim, Tae Min; Kim, Dong-Wan; Kim, Soyeon; Kim, Miso; Alm, Yong-Oon; Keam, Bhumsuk; Heo, Dae Seog

Cancer Research and Treatment, Vol.51 No.3, pp.951-962

DOI
2020-01
HER2-targeted therapies - a role beyond breast cancer

Oh, Do-Youn; Bang, Yung-Jue

Nature Reviews Clinical Oncology, Vol.17 No.1, pp.33-48

DOI
2020-07
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
DOI
2023-12
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
DOI
1